JP7764992B2 - 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 - Google Patents

大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤

Info

Publication number
JP7764992B2
JP7764992B2 JP2021558343A JP2021558343A JP7764992B2 JP 7764992 B2 JP7764992 B2 JP 7764992B2 JP 2021558343 A JP2021558343 A JP 2021558343A JP 2021558343 A JP2021558343 A JP 2021558343A JP 7764992 B2 JP7764992 B2 JP 7764992B2
Authority
JP
Japan
Prior art keywords
proline
peptide
neuropsychological
neuropsychological function
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558343A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021100614A5 (cg-RX-API-DMAC7.html
JPWO2021100614A1 (cg-RX-API-DMAC7.html
Inventor
耕作 大日向
清乃 尾高
琢和 安田
康浩 鹿島
泰治 松川
健二 長田
泰正 山田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uha Mikakuto Co Ltd
Kyoto University
Original Assignee
Uha Mikakuto Co Ltd
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uha Mikakuto Co Ltd, Kyoto University filed Critical Uha Mikakuto Co Ltd
Publication of JPWO2021100614A1 publication Critical patent/JPWO2021100614A1/ja
Publication of JPWO2021100614A5 publication Critical patent/JPWO2021100614A5/ja
Application granted granted Critical
Publication of JP7764992B2 publication Critical patent/JP7764992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021558343A 2019-11-19 2020-11-12 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 Active JP7764992B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019208777 2019-11-19
JP2019208777 2019-11-19
PCT/JP2020/042317 WO2021100614A1 (ja) 2019-11-19 2020-11-12 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤

Publications (3)

Publication Number Publication Date
JPWO2021100614A1 JPWO2021100614A1 (cg-RX-API-DMAC7.html) 2021-05-27
JPWO2021100614A5 JPWO2021100614A5 (cg-RX-API-DMAC7.html) 2022-07-19
JP7764992B2 true JP7764992B2 (ja) 2025-11-06

Family

ID=75981290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021558343A Active JP7764992B2 (ja) 2019-11-19 2020-11-12 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤

Country Status (2)

Country Link
JP (1) JP7764992B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021100614A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022168413A1 (ja) * 2021-02-04 2022-08-11 ユーハ味覚糖株式会社 デプレスタチン含有組成物の製造方法
US20250059233A1 (en) * 2021-12-15 2025-02-20 Viage Therapeutics Inc. Use of therapeutic peptides
JPWO2024117210A1 (cg-RX-API-DMAC7.html) * 2022-12-01 2024-06-06
WO2024259556A1 (en) * 2023-06-19 2024-12-26 Viage Therapeutics, Inc. Uses of therapeutic peptides
EP4743102A1 (en) * 2024-04-15 2026-05-20 Rousselot BV Collagen Peptide Composition and its Use in Reversing Neurological Disorders and Fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010104364A (ja) 2009-09-18 2010-05-13 Uha Mikakuto Co Ltd 神経新生促進剤を含有する飲食品
JP2011111440A (ja) 2009-11-30 2011-06-09 Uha Mikakuto Co Ltd 神経細胞分化促進剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415724B (zh) * 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010104364A (ja) 2009-09-18 2010-05-13 Uha Mikakuto Co Ltd 神経新生促進剤を含有する飲食品
JP2011111440A (ja) 2009-11-30 2011-06-09 Uha Mikakuto Co Ltd 神経細胞分化促進剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KATAYAMA, S. et al.,Oral Administration of Soy Peptides Suppresses Cognitive Decline by Induction of Neurotrophic Factor,J. Agric. Food Chem.,2014年,62,p.3563-3569
MIZUSHIGE, T.,Ginger-Degraded Collagen Hydrolysate Exhibits Antidepressant Activity in Mice,J. Nutr. Sci. Vitaminol.,2019年06月30日,65 (3),p.251-257
MORI, Y. et al.,Characterization of soy-deprestatin, a novel orally active decapeptide that exerts antidepressant-l,FASEB J.,2018年,32,p.568-575
PEI, X. et al.,Marine collagen peptide isolated from Chum Salmon (Oncorhynchus keta) skin facilitates learning and,Food Chemistry,2010年,118,p.333-340
永井研迅 ほか,コラーゲンペプチドPro-Hypの抗うつ作用,第71回日本栄養・食糧学会大会講演要旨集,2017年,p.207, 2A-B40
鹿島康浩 ほか,大豆由来ペプチド配合チュアブル錠が飲用者に与える心理的および生理的な影響評価について ―ランダム化プ,Jpn. Pharmacol. Ther.(薬理と治療),2019年09月20日,47 (9),p.1425-1431

Also Published As

Publication number Publication date
JPWO2021100614A1 (cg-RX-API-DMAC7.html) 2021-05-27
WO2021100614A1 (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
WO2021100614A1 (ja) 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤
JP6189994B2 (ja) ジペプチジルペプチダーゼ−iv阻害用飲食品組成物
JP6344796B2 (ja) 高齢者用アルツハイマー型認知症改善剤
WO2003044044A1 (en) Novel peptide having angiotensin convertase inhibitory effect
JP5976004B2 (ja) ジペプチジルペプチダーゼ−iv阻害剤
JP7358239B2 (ja) エネルギー消費促進用組成物
JP5972235B2 (ja) 血中トリグリセライド低下剤
JP2001031586A (ja) 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
JP7856910B2 (ja) 神経心理学的機能改善剤
JP7787424B2 (ja) デプレスタチン含有組成物の製造方法
CN101909645A (zh) 包含ipp和/或vpp的降血压组合
JP2000312567A (ja) 生理活性健康食品
JP7144441B2 (ja) 抗酸化及び抗高血圧効果を有するヒラメ練肉及びその製造方法
JP2013184962A (ja) ジペプチジルペプチダーゼ−iv阻害剤
CN101795704B (zh) 经口组合物
JP6083085B2 (ja) アンジオテンシン変換酵素阻害剤およびその用途
JP5382633B2 (ja) 脳血管性認知症の予防または治療薬
JP2001026753A (ja) 高血圧症予防又は治療用組成物
JP6589011B2 (ja) 脳機能障害改善用経口組成物
JP6243777B2 (ja) ヒアルロン酸合成促進剤
JP2020152648A (ja) 交感神経活性化用組成物
JP2020097535A (ja) 血圧を降下させるための組成物
JP2005239686A (ja) 脂肪燃焼促進組成物及び該組成物を含有する食品又は医薬品
JP2005255670A (ja) ローヤルゼリー由来の降圧ペプチド
JP2024151925A (ja) 脳内抗酸化酵素活性化組成物

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A527

Effective date: 20220509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251008

R150 Certificate of patent or registration of utility model

Ref document number: 7764992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150